Centessa Pharmaceuticals plc
NASDAQ:CNTA
Overview | Financials
Company Name | Centessa Pharmaceuticals plc |
Symbol | CNTA |
Currency | USD |
Price | 17.16 |
Market Cap | 2,259,270,190 |
Dividend Yield | 0% |
52-week-range | 6.65 - 18.97 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Saurabh Saha M.D., Ph.D. |
Website | https://www.centessa.com |
An error occurred while fetching data.
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD